In heavily pretreated patients with metastatic triple-negative breast cancer (mTNBC), further systemic therapy offers limited benefit and increased toxicity. Recognizing the end-of-life (EOL) phase in time helps avoid overtreatment and ensure goal-concordant care. This study analyzed the interval between the last oncologist visit and death in pretreated women with mTNBC, as well as systemic therapy status, palliative care involvement and related factors. This multinational ambispective cohort study included women with mTNBC who received ≥2 lines of palliative systemic therapy and died between June 20, 2022 and June 20, 2025. Data from 17 centers in Poland, the Czech Republic and Slovakia were extracted from medical records. The primary endpoint was the interval between the final oncologist visit and death. 183 women with median age at death 53.6 years (28.6-86.5) were included. Patients had a median of 4 prior palliative chemotherapy lines (2-12) and the median interval from last oncologist visit to death was 17 days (0-410). At the final visit, 29.5 % continued systemic therapy and 49 % had prior palliative care involvement. Longer intervals were associated with PS 0-1 vs ≥ 2 (p = 0.005), while palliative care involvement had no significant effect (p = 0.849). The results highlight the need for earlier recognition of clinical decline and timely palliative care in mTNBC. Limiting non-beneficial systemic therapy near EOL supports symptom control, autonomy, and quality of life. Despite European efforts, including the Network of Expertise on Complex and Poor Prognosis Cancers, structured EOL planning remains a major gap.
Background: Germline BRCA1/2 mutations may influence sensitivity to systemic therapy in triple-negative breast cancer (TNBC), but their association with outcomes of first-line pembrolizumab plus chemotherapy remains uncertain. This study aimed to assess the association between germline BRCA1/2 mutation status and treatment outcomes in patients with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥10 advanced TNBC receiving first-line pembrolizumab plus chemotherapy. Methods: This planned biomarker subanalysis of the retrospective, 20-centre CEBCC-101 cohort included 139 patients with documented germline BRCA1/2 status (gBRCA1/2m, n = 23; gBRCA1/2wt, n = 116). Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were evaluated using univariable and multivariable analyses. Results: Patients with gBRCA1/2m were younger than those with gBRCA1/2wt (median 51.5 vs. 56.3 years; p = 0.038), with no other significant differences in assessed baseline characteristics. ORR was 78.3% versus 52.2%, respectively (p = 0.038; adjusted OR 6.172, 95% CI 1.581–24.091; p = 0.009). Median PFS was 11.1 versus 8.3 months (log-rank p = 0.181; adjusted HR 0.602, 95% CI 0.331–1.096; p = 0.097) and median OS was 26.1 versus 20.4 months (log-rank p = 0.244; adjusted HR 0.427, 95% CI 0.183–0.996; p = 0.049). No statistically significant differences in the analysed grade ≥ 2 adverse-event categories were detected. Conclusions: In this planned CEBCC-101 subanalysis, documented germline BRCA1/2 status was associated with a higher ORR during first-line pembrolizumab plus chemotherapy. Without a chemotherapy-only comparator, this association cannot be attributed specifically to pembrolizumab and may partly reflect greater sensitivity to DNA-damaging chemotherapy. No statistically significant safety differences were detected. Survival findings remain exploratory.